Vyvanse (Lisdexamfetamine) in Children Under 12: A Complete Guide to Transitioning Care to Adult Providers

What Is Vyvanse and Why Is It Used in Young Children?

Lisdexamfetamine dimesylate (Vyvanse, Takeda) is a prodrug: the lysine moiety renders it pharmacologically inactive until enzymatic cleavage in red blood cells releases d-amphetamine. This conversion mechanism produces a smoother plasma concentration curve compared with immediate-release amphetamine salts and reduces the abuse-extraction value, a relevant consideration even in the pediatric context where diversion risks exist within households.

The FDA approved lisdexamfetamine for ADHD in patients aged 6 and older based on key trial SPD489-301, a randomized, double-blind, placebo-controlled, dose-optimized study (N=290, ages 6 to 12) that demonstrated significant reductions on the ADHD Rating Scale IV (ADHD-RS-IV) total score at all three doses (30 mg, 50 mg, and 70 mg) versus placebo [1]. The drug is listed in the FDA prescribing information as a Schedule II controlled substance, meaning every refill requires a new written prescription.

Why a Prodrug Matters for Children

Children younger than 12 metabolize stimulants differently than adolescents or adults. The prodrug design of lisdexamfetamine keeps peak plasma d-amphetamine levels lower and more consistent than equivalent doses of mixed amphetamine salts, reducing abrupt cardiovascular spikes [2]. A pharmacokinetic study in children aged 6 to 12 showed that dose-normalized exposure (AUC0-inf) was comparable across weight categories when standard weight-based dosing was applied, supporting the fixed-dose titration schema in the label rather than strict milligram-per-kilogram dosing [2].

Indications Beyond ADHD

In adults, lisdexamfetamine carries an additional FDA indication for moderate-to-severe binge eating disorder (BED). That indication does not extend to pediatric patients, and clinicians should document the specific pediatric indication clearly in the chart to avoid confusion during the transition to adult care, where the prescriber may be less familiar with pediatric dosing context.

FDA-Approved Dosing in Children Aged 6 to 11

Dosing follows a structured titration. The prescribing label recommends starting at 20 to 30 mg once daily in the morning, with weekly increases of 10 to 20 mg as tolerated, up to a maximum of 70 mg per day [3].

Titration Protocol

The clinical goal is the lowest effective dose that controls ADHD symptoms across the school day and into early-evening homework hours without producing intolerable appetite suppression or insomnia. Because lisdexamfetamine has a 10 to 14 hour effective duration, a single morning dose typically suffices. No afternoon booster dose is needed or approved in this age group, which is a practical advantage over shorter-acting formulations.

Titration steps used in practice often follow this sequence:

• Week 1: 20 mg or 30 mg every morning
• Week 2: increase to 40 mg if symptom control is insufficient and adverse effects are tolerable
• Week 4: increase to 50 mg if needed
• Week 6 onward: 60 mg or 70 mg only if lower doses are inadequate

The ADHD-RS-IV total score, used as the primary outcome in SPD489-301, dropped by a mean of 18.6 points from baseline at 70 mg versus 8.9 points for placebo (P<0.001) [1].

Monitoring During Dose Titration

Height and weight should be plotted on CDC growth charts at every visit. A landmark 2-year growth study (MTA, N=579) found that children on stimulants gained on average 2.0 cm less in height and 2.7 kg less in weight over 24 months compared with unmedicated peers [4]. The effect is most pronounced in the first year and appears to attenuate with continued treatment, though final adult height data from lisdexamfetamine-specific studies remain limited.

Blood pressure and resting heart rate must also be recorded. The FDA label carries a boxed-adjacent warning about cardiovascular risk, and the American Heart Association recommends an ECG for children with known cardiac disease before initiating any stimulant [5].

Long-Term Safety Data in Pediatric Patients

The 12-month open-label extension study SPD489-325 (N=314, ages 6 to 12) provides the longest controlled-condition dataset specifically for lisdexamfetamine in this age group. Published results showed sustained ADHD-RS-IV score reductions at month 12, with 74.2% of participants maintaining response (defined as 30% or greater reduction from baseline) [6]. Adverse event rates for decreased appetite (35.7%) and insomnia (18.2%) were consistent with the acute trial, with no new safety signals emerging over the extension period.

Cardiovascular Monitoring Over Time

Systolic blood pressure increased by a mean of 1.2 mmHg and diastolic by 1.5 mmHg from baseline over 12 months in SPD489-325, changes that are statistically detectable but clinically modest in otherwise healthy children [6]. A child with a pre-existing arrhythmia or structural heart defect requires cardiology co-management before and during stimulant therapy, per AAP guidance [7].

Growth Monitoring Protocols

The AAP 2019 Clinical Practice Guideline on ADHD states: "Height and weight should be assessed every 6 months in children receiving stimulant medication, with annual plotting on standardized growth curves" [7]. If a child falls below the 10th percentile for weight or drops two major percentile lines for height, a structured drug holiday (typically during summer months) may be considered, though evidence on whether holidays preserve final adult height is mixed.

Sleep and Psychiatric Adverse Effects

Sleep-onset insomnia is reported by approximately 19% of children in controlled trials of lisdexamfetamine. Behavioral sleep hygiene counseling should precede any pharmacological sleep aid in this age group. Clinicians should also screen for new-onset or exacerbated anxiety, as lisdexamfetamine can unmask anxiety disorders in children who have ADHD-anxiety comorbidity. The FDA label lists anxiety, irritability, and emotional lability among the most common psychiatric adverse effects [3].

When and How to Plan the Transition to Adult Care

Transition from pediatric to adult care is one of the highest-risk periods for treatment discontinuation. A 2021 retrospective cohort study in JAMA Pediatrics (N=17,682 adolescents with ADHD) found that stimulant medication coverage dropped by 38% in the 12 months following transfer to an adult provider, with the sharpest drop occurring within the first 90 days of transfer [8].

Structured transition planning substantially reduces this gap. The AAP recommends that transition planning begin between ages 14 and 16, well before the actual handoff [7].

The Six Core Elements of a Vyvanse Transition Plan

1. Medication summary document. Prepare a single-page record listing the current lisdexamfetamine dose, titration history, documented therapeutic response metrics (ADHD-RS-IV or Vanderbilt scores), and adverse effects encountered at each dose level.

2. Growth trajectory handoff. Send the pediatric growth chart to the adult provider so that baseline height and weight context is preserved. Adult providers rarely have access to pediatric growth data by default.

3. Controlled-substance continuity plan. Schedule II rules require that the new adult prescriber evaluate the patient before writing the first prescription. Schedule the adult intake appointment at least 30 days before the last pediatric refill expires to avoid a coverage gap.

4. Comorbidity summary. ADHD in children under 12 has a 30 to 50% comorbidity rate with anxiety, oppositional defiant disorder, or mood disorders [9]. The adult provider needs this context to avoid misattributing stimulant side effects to new psychiatric diagnoses.

5. Patient and family education. Adolescents transitioning to adult care often shift to self-managing their prescriptions for the first time. Structured psychoeducation about Schedule II logistics, diversion risks, and self-monitoring of blood pressure reduces the probability of gaps.

6. Follow-up confirmation. The pediatric team should confirm, in writing, that the first adult-care appointment has been kept. A 30-day check-in call from the pediatric practice reduces 90-day drop-off.

Legal and Administrative Considerations

Because lisdexamfetamine is Schedule II, adult providers cannot simply accept a transfer of care note and call in refills. The DEA requires a face-to-face evaluation before the first prescription in most states, and several states impose additional record-keeping requirements. Families should be counseled on this at least two months in advance, not two weeks.

The HealthRX Pediatric-to-Adult ADHD Transition Checklist (see framework above) operationalizes the six elements above into a single clinical workflow designed for telehealth-based adult ADHD practices receiving transferred pediatric patients.

What Changes When a Child Moves to Adult Care

Several pharmacological and clinical parameters shift when the patient ages out of pediatric services.

Dosing Continuity

The FDA-approved adult maximum dose for lisdexamfetamine remains 70 mg/day, identical to the pediatric maximum. No upward dose adjustment is warranted simply because the patient has aged into an adult care setting. Adult providers sometimes interpret the pediatric dose as conservative and escalate unnecessarily. The prescribing label does not recommend dose increases at the time of transition without new clinical justification [3].

Comorbidity Re-evaluation

Adult ADHD frequently presents with comorbid substance use disorder, depression, or anxiety at higher rates than in the pediatric population. A 2020 meta-analysis in The Lancet Psychiatry (pooled N=76,000 adults with ADHD) found that 47% had at least one psychiatric comorbidity diagnosed after age 18 [10]. The adult provider should conduct a full psychiatric intake, not simply renew the pediatric prescription.

Monitoring Parameter Shifts

Growth monitoring becomes irrelevant after epiphyseal closure, typically by age 18. The monitoring focus shifts to:

• Blood pressure and heart rate (annual minimum, more frequently if hypertension is present)
• Substance use screening (annually with a validated tool such as AUDIT-C or DAST-10)
• Medication adherence and diversion risk
• Cardiovascular risk factors that become more clinically significant with age

Special Populations and Edge Cases

Children With Intellectual Disabilities or Developmental Delays

Stimulant response rates in children with ADHD and comorbid intellectual disability are lower than in typically developing children. A Cochrane review (Simonoff et al., 2013, N=15 trials) found that effect sizes for methylphenidate in children with intellectual disability were approximately half those seen in children without intellectual disability [11]. Lisdexamfetamine-specific data in this subgroup are limited, and clinicians should apply particularly conservative titration and document target behaviors in observable, measurable terms to guide dose decisions.

Children With Autism Spectrum Disorder

ASD and ADHD co-occur in approximately 50 to 70% of cases per CDC prevalence estimates [12]. Stimulants in children with ASD may produce more pronounced irritability and emotional dysregulation. The RUPP Autism Network trial (N=72) showed a 49% response rate for methylphenidate in this population versus 69% in typically developing children, with a higher rate of adverse effects leading to discontinuation (18% vs. 1.7%) [13]. These findings may extend to lisdexamfetamine, and extra caution during titration is warranted.

Weight Considerations at Transition

Children who experienced significant weight suppression during years of stimulant therapy may show rebound weight gain in adolescence, particularly if dose is reduced or discontinued at transition. A 2018 study in Pediatrics (N=1,267) found that adults who had been on stimulants continuously from childhood had body mass indexes statistically similar to stimulant-naive controls by their early 20s, suggesting the growth-suppression effect is largely reversible [14]. Reassuring families about this trajectory at the transition meeting can improve adherence to the medication plan.

Documentation Practices That Support Successful Transitions

Incomplete documentation is the single most common failure point in pediatric-to-adult transitions for controlled substances. Adult providers must independently justify Schedule II prescriptions under DEA regulations, and a thin chart places both the patient and the prescriber at risk.

The minimum documentation package for a Vyvanse transition should include:

• Diagnosis date and initial diagnostic criteria (DSM-5 or DSM-IV if diagnosed before 2013)
• All dose changes with dates and rationale
• At least two structured rating scales from the past 12 months (teacher and parent Vanderbilt or ADHD-RS)
• Growth chart data for the previous 3 years
• Any prior trials of other stimulants or non-stimulant medications (atomoxetine, guanfacine, clonidine) with outcomes
• Current blood pressure and heart rate readings
• Any psychiatric hospitalizations or emergency visits

The AAP's "Got Transition" program provides standardized transition readiness assessment tools validated for use in adolescents with chronic conditions, including ADHD [15]. Using a validated tool creates defensible documentation and improves the probability that the adult provider will accept the transition summary.

Frequently Asked Questions